rs1078749
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_021629.4(GNB4):āc.48T>Cā(p.Asn16=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0349 in 1,601,692 control chromosomes in the GnomAD database, including 1,195 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.035 ( 127 hom., cov: 32)
Exomes š: 0.035 ( 1068 hom. )
Consequence
GNB4
NM_021629.4 synonymous
NM_021629.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.655
Genes affected
GNB4 (HGNC:20731): (G protein subunit beta 4) Heterotrimeric guanine nucleotide-binding proteins (G proteins), which integrate signals between receptors and effector proteins, are composed of an alpha, a beta, and a gamma subunit. These subunits are encoded by families of related genes. This gene encodes a beta subunit. Beta subunits are important regulators of alpha subunits, as well as of certain signal transduction receptors and effectors. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.49).
BP6
Variant 3-179426153-A-G is Benign according to our data. Variant chr3-179426153-A-G is described in ClinVar as [Benign]. Clinvar id is 414883.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-179426153-A-G is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=0.655 with no splicing effect.
BA1
GnomAdExome4 highest subpopulation (MID) allele frequency at 95% confidence interval = 0.128 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GNB4 | NM_021629.4 | c.48T>C | p.Asn16= | synonymous_variant | 2/10 | ENST00000232564.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GNB4 | ENST00000232564.8 | c.48T>C | p.Asn16= | synonymous_variant | 2/10 | 1 | NM_021629.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0348 AC: 5302AN: 152230Hom.: 126 Cov.: 32
GnomAD3 genomes
AF:
AC:
5302
AN:
152230
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0333 AC: 7948AN: 238918Hom.: 188 AF XY: 0.0343 AC XY: 4426AN XY: 129214
GnomAD3 exomes
AF:
AC:
7948
AN:
238918
Hom.:
AF XY:
AC XY:
4426
AN XY:
129214
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0349 AC: 50648AN: 1449344Hom.: 1068 Cov.: 29 AF XY: 0.0349 AC XY: 25171AN XY: 720798
GnomAD4 exome
AF:
AC:
50648
AN:
1449344
Hom.:
Cov.:
29
AF XY:
AC XY:
25171
AN XY:
720798
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0348 AC: 5303AN: 152348Hom.: 127 Cov.: 32 AF XY: 0.0340 AC XY: 2531AN XY: 74504
GnomAD4 genome
AF:
AC:
5303
AN:
152348
Hom.:
Cov.:
32
AF XY:
AC XY:
2531
AN XY:
74504
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
40
AN:
3474
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 30, 2019 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Charcot-Marie-Tooth disease dominant intermediate F Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at